Federated Hermes, a global investment firm, announced the availability of monthly fund composition and performance data for its Premier Municipal Income Fund as of August 31, 2026. Investors can access this information online or request hard copies via phone, email, or mail. This update reflects Federated Hermes' ongoing transparency and support for its clients, who include a wide range of institutional investors worldwide. The firm manages $911.6 billion in assets and offers diverse investment strategies across multiple asset classes.
Federated Hermes Premier Municipal Income Fund's monthly portfolio data is now available, providing investors with updated transparency. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 15, 2026 22:53 WIB: out of 74 priced US Financials stocks tradable on Pluang, 11 rose and 62 fell. Notable movers include BNY (Bank of New York Mellon Corp) at USD 152.67 with a -3.17% change, GS (Goldman Sachs Group Inc) at USD 957.74 with a -3.11% change, and ALLY (Ally Financial Inc) at USD 40.64 with a -3.10% change.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
